{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T17:25:07Z","timestamp":1782581107668,"version":"3.54.5"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,28]],"date-time":"2018-07-28T00:00:00Z","timestamp":1532736000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["15-15-00102"],"award-info":[{"award-number":["15-15-00102"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12865-018-0264-x","type":"journal-article","created":{"date-parts":[[2018,7,28]],"date-time":"2018-07-28T07:23:26Z","timestamp":1532762606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-9299","authenticated-orcid":false,"given":"Ekaterina","family":"Lebedeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Bagaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Pichugin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Chulkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Lysenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Tutykhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"Shmarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Logunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Naroditsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravshan","family":"Ataullakhanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,28]]},"reference":[{"key":"264_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrc3670","volume":"14","author":"PG Coulie","year":"2014","unstructured":"Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14:135\u201346.","journal-title":"Nat Rev Cancer"},{"key":"264_CR2","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nm.f.1774","volume":"14","author":"V Appay","year":"2008","unstructured":"Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med. 2008;14:623\u20138.","journal-title":"Nat Med"},{"key":"264_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1365-2567.2011.03517.x","volume":"135","author":"SC Gilbert","year":"2011","unstructured":"Gilbert SC. T-cell-inducing vaccines - what\u2019s the future. Immunology. 2011;135:19\u201326.","journal-title":"Immunology"},{"key":"264_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.coi.2016.06.007","volume":"41","author":"SG Reed","year":"2016","unstructured":"Reed SG, Hsu FC, Carter D, Orr MT. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants. Curr Opin Immunol. 2016;41:85\u201390.","journal-title":"Curr Opin Immunol"},{"key":"264_CR5","doi-asserted-by":"publisher","first-page":"5886","DOI":"10.1016\/j.vaccine.2016.10.036","volume":"34","author":"E Poteet","year":"2016","unstructured":"Poteet E, Lewis P, Chen C, Ho SO, Do T, Chiang SM, et al. Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. Vaccine. 2016;34:5886\u201394.","journal-title":"Vaccine"},{"key":"264_CR6","doi-asserted-by":"publisher","first-page":"e0149610","DOI":"10.1371\/journal.pone.0149610","volume":"11","author":"N Van Hoeven","year":"2016","unstructured":"Van Hoeven N, Joshi SW, Nana GI, Bosco-Lauth A, Fox C, Bowen RA, et al. A novel synthetic TLR-4 agonist adjuvant increases the protective response to a clinical-stage West Nile virus vaccine antigen in multiple formulations. PLoS One. 2016;11:e0149610.","journal-title":"PLoS One"},{"key":"264_CR7","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.4049\/jimmunol.1202958","volume":"190","author":"H Park","year":"2013","unstructured":"Park H, Adamson L, Ha T, Mullen K, Hagen SI, Nogueron A, et al. Polyinosinic-polycytidylic acid is the most effective TLR adjuvant for SIV gag protein-induced T cell responses in nonhuman primates. J Immunol. 2013;190:4103\u201315.","journal-title":"J Immunol"},{"key":"264_CR8","first-page":"235","volume-title":"Immunother Cancer","author":"S Tsukasa","year":"2016","unstructured":"Tsukasa S, Azuma M, Matsumoto M. Pattern recognition by dendritic cells and its application to vaccine adjuvant for antitumor immunotherapy. In: Immunother Cancer. Tokyo: Springer; 2016. p. 235\u201346."},{"key":"264_CR9","doi-asserted-by":"publisher","first-page":"7670","DOI":"10.4049\/jimmunol.181.11.7670","volume":"181","author":"SM Ngoi","year":"2009","unstructured":"Ngoi SM, Tovey MG, Vella AT. Targeting poly I:C to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN\u03b1\/\u03b2. J Immunol. 2009;181:7670\u201380.","journal-title":"J Immunol"},{"key":"264_CR10","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.vaccine.2007.12.012","volume":"26","author":"J Geurtsen","year":"2008","unstructured":"Geurtsen J, Fransen F, Vandebriel RJ, Gremmer ER, de la Fonteyne-Blankestijn LJJ, Kuipers B, et al. Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses. Vaccine. 2008;26:899\u2013906.","journal-title":"Vaccine"},{"key":"264_CR11","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1016\/j.vaccine.2009.04.047","volume":"27","author":"W Quintilio","year":"2009","unstructured":"Quintilio W, Kubrusly FS, Iourtov D, Miyaki C, Sakauchi MA, L\u00facio F, et al. Bordetella pertussis monophosphoryl lipid a as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine. 2009;27:4219\u201324.","journal-title":"Vaccine"},{"key":"264_CR12","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1016\/j.vaccine.2006.04.010","volume":"24","author":"ML Salem","year":"2006","unstructured":"Salem ML, SA EL-N, Kadima A, Gillanders WE, Cole DJ. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine. 2006;24:5119\u201332.","journal-title":"Vaccine"},{"key":"264_CR13","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1172\/JCI39293","volume":"120","author":"Q Zhu","year":"2010","unstructured":"Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest. 2010;120:607\u201316.","journal-title":"J Clin Invest"},{"key":"264_CR14","doi-asserted-by":"publisher","first-page":"16030","DOI":"10.1038\/mtm.2016.30","volume":"3","author":"S Afkhami","year":"2016","unstructured":"Afkhami S, Yao Y, Xing Z. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Mol Ther Methods Clin Dev. 2016;3:16030.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"264_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/14760584.2016.1228454","volume":"16","author":"MR Hollingdale","year":"2016","unstructured":"Hollingdale MR, Sedegah M, Limbach K. Development of replication-deficient adenovirus malaria vaccines. Expert Rev Vaccines. 2016;16:261\u201371.","journal-title":"Expert Rev Vaccines"},{"key":"264_CR16","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1016\/j.vaccine.2016.04.090","volume":"34","author":"CF Shen","year":"2016","unstructured":"Shen CF, Jacob D, Zhu T, Bernier A, Shao Z, Yu X, et al. Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate. Vaccine. 2016;34:3381\u20137.","journal-title":"Vaccine"},{"key":"264_CR17","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1097\/QAD.0000000000001122","volume":"30","author":"PJ Hayes","year":"2016","unstructured":"Hayes PJ, Cox JH, Coleman AR, Fernandez N, Bergin PJ, Kopycinski JT, et al. Adenovirus-based HIV-1 vaccine candidates tested in efficacy trials elicit CD8+ T cells with limited breadth of HIV-1 inhibition. AIDS. 2016;30:1703\u201312.","journal-title":"AIDS"},{"key":"264_CR18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1021\/acs.molpharmaceut.5b00802","volume":"13","author":"M Li","year":"2016","unstructured":"Li M, Jiang Y, Gong T, Zhang Z, Sun X. Intranasal vaccination against HIV-1 with adenoviral vector-based Nanocomplex using synthetic TLR-4 agonist peptide as adjuvant. Mol Pharm. 2016;13:885\u201394.","journal-title":"Mol Pharm"},{"key":"264_CR19","doi-asserted-by":"publisher","first-page":"e9579","DOI":"10.1371\/journal.pone.0009579","volume":"5","author":"DM Appledorn","year":"2010","unstructured":"Appledorn DM, Aldhamen YA, DePas W, Seregin SS, Liu CJJ, Schuldt N, et al. A new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic target. PLoS One. 2010;5:e9579.","journal-title":"PLoS One"},{"key":"264_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1365-3083.2006.01706.x","volume":"63","author":"V Salucci","year":"2006","unstructured":"Salucci V, Mennuni C, Calvaruso F, Cerino R, Neuner P, Ciliberto G, et al. CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a toll-like receptor ligand. Scand J Immunol. 2006;63:35\u201341.","journal-title":"Scand J Immunol"},{"key":"264_CR21","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.vaccine.2013.01.023","volume":"31","author":"W Peters","year":"2013","unstructured":"Peters W, Brandl JR, Lindbloom JD, Martinez CJ, Scallan CD, Trager GR, et al. Oral administration of an adenovirus vector encoding both an avian influenza a hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-\u03b3 T cell responses in humans. Vaccine. 2013;31:1752\u20138.","journal-title":"Vaccine"},{"key":"264_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1128\/CVI.00552-12","volume":"20","author":"CD Scallan","year":"2013","unstructured":"Scallan CD, Tingley DW, Lindbloom JD, Toomey JS, Tucker SN. An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models. Clin Vaccine Immunol. 2013;20:85\u201394.","journal-title":"Clin Vaccine Immunol"},{"key":"264_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1128\/CVI.00341-10","volume":"18","author":"DM Appledorn","year":"2011","unstructured":"Appledorn DM, Aldhamen YA, Godbehere S, Seregin SS, Amalfitano A. Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immuni. Clin Vaccine Immunol. 2011;18:150\u201360.","journal-title":"Clin Vaccine Immunol"},{"key":"264_CR24","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1128\/CVI.00251-16","volume":"23","author":"KA Hofmeyer","year":"2016","unstructured":"Hofmeyer KA, Duthie MS, Laurance JD, Favila MA, Van Hoeven N, Coler RN, et al. Optimizing immunization strategies for the induction of antigen-specific CD4 and CD8 T cell responses for protection against intracellular parasites. Clin Vaccine Immunol. 2016;23:785\u201394.","journal-title":"Clin Vaccine Immunol"},{"key":"264_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1128\/JVI.01597-10","volume":"85","author":"EG Rhee","year":"2011","unstructured":"Rhee EG, Blattman JN, Kasturi SP, Kelley RP, Kaufman DR, Lynch DM, et al. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J Virol. 2011;85:315\u201323.","journal-title":"J Virol"},{"key":"264_CR26","doi-asserted-by":"publisher","first-page":"10413","DOI":"10.1128\/JVI.00928-10","volume":"84","author":"EG Rhee","year":"2010","unstructured":"Rhee EG, Kelley RP, Agarwal I, Lynch DM, La Porte A, Simmons NL, et al. TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector. J Virol. 2010;84:10413\u20139.","journal-title":"J Virol"},{"key":"264_CR27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1172\/JCI78280","volume":"125","author":"KM Quinn","year":"2015","unstructured":"Quinn KM, Zak DE, Costa A, Yamamoto A, Kastenmuller K, Hill BJ, et al. Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. J Clin Invest. 2015;125:1129\u201346.","journal-title":"J Clin Invest"},{"key":"264_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/intimm\/dxv058","volume":"28","author":"S Tsuzuki","year":"2016","unstructured":"Tsuzuki S, Tachibana M, Hemmi M, Yamaguchi T, Shoji M, Sakurai F, et al. TANK-binding kinase 1-dependent or -independent signaling elicits the cell-type-specific innate immune responses induced by the adenovirus vector. Int Immunol. 2016;28:105\u201315.","journal-title":"Int Immunol"},{"key":"264_CR29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.32607\/20758251-2014-6-4-27-39","volume":"6","author":"AV Bagaev","year":"2014","unstructured":"Bagaev AV, Pichugin AV, Lebedeva ES, Lysenko AA, Shmarov MM, Logunov DY, et al. Regulation of the target protein (transgene) expression in the adenovirus vector using agonists of toll-like receptors. Acta Nat. 2014;6:27\u201339.","journal-title":"Acta Nat"},{"key":"264_CR30","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/jlb.67.5.607","volume":"67","author":"SR Clarke","year":"2000","unstructured":"Clarke SR. The critical role of CD40\/CD40L in the CD4-dependent generation of CD8+ T cell immunity. J Leukoc Biol. 2000;67:607\u201314.","journal-title":"J Leukoc Biol"},{"key":"264_CR31","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1084\/jem.20021910","volume":"197","author":"JM Curtsinger","year":"2003","unstructured":"Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med. 2003;197:1141\u201351.","journal-title":"J Exp Med"},{"key":"264_CR32","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.4049\/jimmunol.162.6.3256","volume":"162","author":"JM Curtsinger","year":"1999","unstructured":"Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, et al. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells. J Immunol. 1999;162:3256\u201362.","journal-title":"J Immunol"},{"key":"264_CR33","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1365-2567.2011.03412.x","volume":"132","author":"JP Huber","year":"2011","unstructured":"Huber JP, David FJ. Regulation of effector and memory T-cell functions by type I interferon. Immunology. 2011;132:466\u201374.","journal-title":"Immunology"},{"key":"264_CR34","doi-asserted-by":"publisher","first-page":"e1002352","DOI":"10.1371\/journal.ppat.1002352","volume":"8","author":"RM Welsh","year":"2012","unstructured":"Welsh RM, Bahl K, Marshall HD, Urban SL. Type 1 interferons and antiviral CD8 T-cell responses. PLoS Pathog. 2012;8:e1002352.","journal-title":"PLoS Pathog"},{"key":"264_CR35","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2011-05-357111","volume":"118","author":"FZ Chowdhury","year":"2011","unstructured":"Chowdhury FZ, Ramos HJ, Davis LS, Forman J, Farrar JD. IL-12 selectively programs effector pathways that are stably expressed in human CD8 + effector memory T cells in vivo. Blood. 2011;118:3890\u2013900.","journal-title":"Blood"},{"key":"264_CR36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.0105-2896.2006.00382.x","volume":"211","author":"MF Mescher","year":"2006","unstructured":"Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev. 2006;211:81\u201392.","journal-title":"Immunol Rev"},{"key":"264_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0092-8674(95)90070-5","volume":"81","author":"H Hsu","year":"1995","unstructured":"Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-\u03baB activation. Cell. 1995;81:495\u2013504.","journal-title":"Cell"},{"key":"264_CR38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri2314","volume":"8","author":"AJ Sadler","year":"2009","unstructured":"Sadler AJ, Bryan RG. Williams. Interferon-inducible antiviral effectors. Nat Rev Immunol. 2009;8:559\u201368.","journal-title":"Nat Rev Immunol"},{"key":"264_CR39","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1002\/ijc.22873","volume":"121","author":"D Karan","year":"2007","unstructured":"Karan D, Krieg AM, Lubaroff DM. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer. 2007;121:1520\u20138.","journal-title":"Int J Cancer"},{"key":"264_CR40","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.vaccine.2011.10.086","volume":"30","author":"THT Brown","year":"2012","unstructured":"Brown THT, David J, Acosta-Ramirez E, Moore JM, Lee S, Zhong G, et al. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG\/HH2 adjuvanted-subunit vaccines against genital chlamydia muridarum infection. Vaccine. 2012;30:350\u201360.","journal-title":"Vaccine"},{"key":"264_CR41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.virol.2014.08.012","volume":"468","author":"F Diaz-San Segundo","year":"2014","unstructured":"Diaz-San Segundo F, Dias CC, Moraes MP, Weiss M, Perez-Martin E, Salazar AM, et al. Poly ICLC increases the potency of a replication-defective human adenovirus vectored foot-and-mouth disease vaccine. Virology. 2014;468:283\u201392.","journal-title":"Virology"},{"key":"264_CR42","doi-asserted-by":"publisher","first-page":"e54126","DOI":"10.1371\/journal.pone.0054126","volume":"8","author":"X Chuai","year":"2013","unstructured":"Chuai X, Chen H, Wang W, Deng Y, Wen B, Ruan L, et al. Poly(I:C)\/alum mixed adjuvant priming enhances HBV subunit vaccine-induced immunity in mice when combined with recombinant adenoviral-based HBV vaccine boosting. PLoS One. 2013;8:e54126.","journal-title":"PLoS One"},{"key":"264_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/rmv.600","volume":"19","author":"Y-M Wen","year":"2009","unstructured":"Wen Y-M, Wang Y-X. Biological features of hepatitis B virus isolates from patients based on full-length genomic analysis. Rev Med Virol. 2009;19:57\u201364.","journal-title":"Rev Med Virol"},{"key":"264_CR44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0966-842X(00)01845-X","volume":"8","author":"R Medzhitov","year":"2000","unstructured":"Medzhitov R, Janeway C. The toll receptor family and microbial recognition. Trends Microbiol. 2000;8:452\u20136.","journal-title":"Trends Microbiol"},{"key":"264_CR45","unstructured":"Ataullakhonov RI, Pichugin AV, Melnikova TM, Khaitov RM. Method of producing a substance with antimicrobial, antiviral, and immunostimulatory activities, a substance and a composition. In: Patents.com . 2015. http:\/\/patents.com\/us-20160263175.html . Accessed 5 Jul 2018."},{"key":"264_CR46","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.4049\/jimmunol.1701126","volume":"200","author":"A Bagaev","year":"2018","unstructured":"Bagaev A, Pichugin A, Nelson EL, Agadjanyan MG, Ghochikyan A, Ataullakhanov RI. Anticancer mechanisms in two murine bone marrow\u2013derived dendritic cell subsets activated with TLR4 agonists. J Immunol. 2018;200:2656\u201369.","journal-title":"J Immunol"},{"key":"264_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-014-0322-y","volume":"12","author":"A Ghochikyan","year":"2014","unstructured":"Ghochikyan A, Pichugin A, Bagaev A, Davtyan A, Hovakimyan A, Tukhvatulin A, et al. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax, as a therapeutic strategy for metastatic breast cancer. J Transl Med. 2014;12:1\u201312.","journal-title":"J Transl Med"},{"key":"264_CR48","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.4049\/jimmunol.1302806","volume":"192","author":"NM Provine","year":"2014","unstructured":"Provine NM, Larocca RA, Penaloza-MacMaster P, Borducchi EN, McNally A, Parenteau LR, et al. Longitudinal requirement for CD4+ T cell help for adenovirus vector-elicited CD8+ T cell responses. J Immunol. 2014;192:5214\u201325.","journal-title":"J Immunol"},{"key":"264_CR49","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1128\/JVI.00039-16","volume":"90","author":"NM Provine","year":"2016","unstructured":"Provine NM, Badamchi-Zadeh A, Bricault CA, Penaloza-MacMaster P, Larocca RA, Borducchi EN, et al. Transient CD4 + T cell depletion results in the delayed development of functional vaccine-elicited antibody responses. J Virol. 2016;90:4278\u201388.","journal-title":"J Virol"},{"key":"264_CR50","doi-asserted-by":"publisher","first-page":"13994","DOI":"10.1073\/pnas.1510760112","volume":"112","author":"W Hu","year":"2015","unstructured":"Hu W, Jain A, Gao Y, Dozmorov IM, Mandraju R, Wakeland EK, et al. Differential outcome of TRIF-mediated signaling in TLR4 and TLR3 induced DC maturation. Proc Natl Acad Sci. 2015;112:13994\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"264_CR51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2013","unstructured":"Elgueta R, Benso MJ, de Vries VS, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol Rev. 2013;229:152\u201372.","journal-title":"Immunol Rev"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-018-0264-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12865-018-0264-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-018-0264-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:50:35Z","timestamp":1693788635000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-018-0264-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,28]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["264"],"URL":"https:\/\/doi.org\/10.1186\/s12865-018-0264-x","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,28]]},"assertion":[{"value":"2 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was carried out in accordance with the Russian Guidelines for the Care and Use of Laboratory Animals. The protocol was approved by the local ethics committee of the Institute of Immunology of FMBA Russia (Order of November 12, 2015), certified by the Local Ethics Committee (Resolution 4\/17 of July 13, 2017).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"26"}}